Is Cyclo Therapeutics, Inc. (CYTH) a Buy, Sell, or Hold?
NASDAQ : CYTH
Cyclo Therapeutics, Inc.
$0.7206 USD
$0 (0.0%)
- Volume
- 186.81K
- Average Volume
- 1.86M
- Market Capitalization
- $23.59M
- P/E Ratio
- -0.59
- Dividend Yield
- 0.00%
- Price Target
- $0.95
- Year High
- $1.62
- Year Low
- $0.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.45
Company Overview
NASDAQ
N. Scott Fine
Drug Manufacturers - Specialty & Generic
Healthcare
CYTH
8
US
USD
Liquidity Metrics
0.22
1.45
1.42
1.09
0.00
Sales & Valuation
$1.08M
21.92
2.47
-1.46
-0.99
Profitability
-$1.23
-$20.06M
-1863.36%
-1863.36%
-730.48%
-151.40%
P/E Metrics
-0.59
-0.01
-0.01
Analyst Price Target & Rating
$0.95
$0.95
$0.95
0/5
3 Analysts
-24.15%
Financial Health Scores
-45.56
3/9
-$15.46M
$5.25M
$18.73M
-$24.68M
Key Metrics (TTM)
$15.38M
14.28
-0.77
1.45
-730.48%
-294.82%
-170.45%
-68.62%
-17020 days
Company Executives
| Name | Title |
|---|---|
| Karen Mullen | Interim Chief Medical Officer |
| C. E Strattan | Founder & Director |
| Joshua Fine | Chief Financial Officer & Secretary |
| Michael Eric Lisjak | Senior Vice President of Business Development & Chief Regulatory Officer |
| N. Scott Fine | Chief Executive Officer & Director |
| Lori McKenna | Global Head of Patient Advocacy |
| Jeffrey L. Tate | Chief Operating Officer, Chief Quality Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Stock
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 20 ... 19 and maintains its headquarters in Gainesville, Florida.
Frequently Asked Questions
-
What is the current Cyclo Therapeutics, Inc. (CYTH) stock price?
-
Cyclo Therapeutics, Inc.(NASDAQ:CYTH) stock price is $0.7206 in the last trading session. During the trading session, CYTH stock reached the peak price of $1.6199 while $0.55 was the lowest point it dropped to. The percentage change in CYTH stock occurred in the recent session was 0.0% while the dollar amount for the price change in CYTH stock was $0.
-
CYTH's industry and sector of operation?
-
The NASDAQ listed CYTH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of CYTH?
-
Karen Mullen | Interim Chief Medical Officer
C. E Strattan | Founder & Director
Joshua Fine | Chief Financial Officer & Secretary
Michael Eric Lisjak | Senior Vice President of Business Development & Chief Regulatory Officer
N. Scott Fine | Chief Executive Officer & Director -
How many employees does CYTH have?
-
Number of CYTH employees currently stands at 8. CYTH operates from 6714 NW 16th Street, Gainesville, FL 32653, US.
-
Link for CYTH official website?
-
Official Website of CYTH is: https://www.cyclotherapeutics.com
-
How do I contact CYTH?
-
CYTH could be contacted at phone #386 418 8060 and can also be accessed through its website. CYTH operates from 6714 NW 16th Street, Gainesville, FL 32653, US.
-
How many shares of CYTH are traded daily?
-
The average number of CYTH shares traded daily for last 3 months was 1.86M.
-
What is the market cap of CYTH currently?
-
The market value of CYTH currently stands at $23.59M with its latest stock price at $0.7206